Société Française
de Thérapie Cellulaire
et Génique
SFTCG

09:30 **Registration, welcome coffee**

10:30 **Session 1: From virus to vector**

INV01 Els Verhoeyen, *University of Nice*
Turning HIV into a therapeutic vector
INV02 Eduard Ayuso, *University of Nantes*
Converting adeno-associated viruses into therapeutic drugs
INV03 Karim Benihoud, *Institut Gustave Roussy, Paris*
Vaccine strategies based on adenovirus-derived vectors

OR01 Youna Coquin, *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*
Lentiviral vectors pseudotyped with murine syncytins-A or -B transduce B cells *in vitro* and *in vivo*
OR02 Laura Muraine, *Institut de Myologie, Paris*
Transduction efficiency of AAV 1 to 10 serotypes after local intramuscular injection in mouse
OR03 Julie Chassagne, *Sorbonne Université UPMC Univ Paris 06*
RFX1 and RFX3 transcription factors interact with the D Sequence of adeno-associated virus inverted terminal repeat and regulate AAV transduction

12:15 **Lunch & posters**

13:30 **Session 2: Engineering research applications**

INV04 Philippe Mangeot, *ENS Lyon*
Genome editing in primary cells using viral-like particles loaded with Cas9-sgRNA ribonucleoproteins.
INV05 Deniz Dalkara, *Institut de la Vision, Paris*
AAV vectors: design and applications in the retina
INV06 Pascal Fender, *Institut de Biologie Structurale, Grenoble*
Adenovirus dodecahedron a Swiss knife to study viral tropism and beyond

OR04 Grégoire Culot, *Université Bordeaux Segalen*
CRISPR-Cas9 genome editing: molecular scissors a bit too sharp?
OR05 Guillaume Corre, *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*
Induction of DNA methylation in CD34+ cells following lentiviral vector infection
OR06 Dominique Van Looveren, *KU Leuven*
Assessing functionality and potential of the next generation BET-independent integrase-CBX MLV vector for safer gene therapy
OR07 Karine Sii Felice, *CEA, Paris*
Enhanced transduction of Macaca fascicularis hematopoietic cells with chimeric lentiviral vectors

15:20 **Coffee break**

15:45 **Session 3: Clinical applications**

INV07 Paula Rio, *CIEMAT Ciberer, Madrid*
Update on the Fanconi anaemia clinical trial
INV08 Federico Mingozzi, *Spark Therapeutics, Philadelphia*
Gene transfer for Pompe disease, turning the liver into a depot for acid alpha-glucosidase
INV09 Kerry Fisher, *University of Oxford*
Clinical applications of replicating gene delivery vectors

OR09 David Dries, *KU Leuven*
Lentiviral vectors expressing CTNS rescue cystine content in cystinotic fibroblasts
OR08 Rebecca Xicluna, *Université de Nantes*
Characterization of anti-AAV viral pre-existing cellular immune responses in humans
OR10 Gaëlle Chaveau, *Genethon, UMR_S951, Inserm, Univ Evry, Université Paris Saclay, EPHE*
Subretinal injection of high dose of rAAV2/8 vector induces retinal alteration and systemic anti-transgene T-cell response, but no local massive immune infiltrate

17:40 **Closing drinks, posters & awards**